Application of routine monitoring data for determination of the population pharmacokinetics and enteral bioavailability of phenytoin in neonates and infants with seizures

Mohammed Al Za'abi, Anders Lanner, Xiao Xiaonian, Timothy Donovan, Bruce Charles

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

This study investigated the population pharmacokinetics and the enteral bioavailability of phenytoin (PTN) in neonates and infants with seizures. Data from 83 patients were obtained retrospectively from medical records. A 1-compartment model was fitted to the log-transformed concentration data using NONMEM. Between-subject variability and interoccasion variability were modelled exponentially together with a log transform, both-sides exponential residual unexplained variance model. Covariates in nested models were screened for significance. Model robustness was assessed by bootstrapping with replacement (n = 500) from the study data. The parameters of the final pharmacokinetic model were clearance (L/h) = 0.826·[weight (WT, kg) ÷ 70]·[1 + 0.0692·(postnatal age (d) - 11)]; volume of distribution (L) = 74.2·[WT (kg) ÷ 70]; absolute enteral bioavailability = 0.76; absorption rate constant (h) = 0.167. The between-subject variability for clearance and volume of distribution was 74.2% and 65.6%, respectively. The interoccasion variability for clearance was 54.4%. The unexplained variability was 51.1%. Final model parameter values deviated from median bootstrap estimates by less than 9%. Phenytoin disposition in neonates and infants can be described satisfactorily by linear pharmacokinetics. The values of allometrically scaled clearance and volume were similar to adult values, suggesting no major kinetic differences between adults and infants on the basis of size alone. Postnatal age independently influenced clearance. Switching from enteral to intravenous routes may require a dosage adjustment. The results of this study provide a basis for more rational prescribing of phenytoin in infants and neonates.

Original languageEnglish
Pages (from-to)793-799
Number of pages7
JournalTherapeutic Drug Monitoring
Volume28
Issue number6
DOIs
Publication statusPublished - Dec 2006

Fingerprint

Pharmacokinetics
Phenytoin
Biological Availability
Small Intestine
Seizures
Newborn Infant
Monitoring
Population
Medical Records
Weights and Measures
Rate constants
Kinetics

Keywords

  • Enteral bioavailability
  • Infants
  • NONMEM
  • Pharmacokinetics
  • Phenytoin

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis
  • Pharmacology
  • Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health

Cite this

Application of routine monitoring data for determination of the population pharmacokinetics and enteral bioavailability of phenytoin in neonates and infants with seizures. / Za'abi, Mohammed Al; Lanner, Anders; Xiaonian, Xiao; Donovan, Timothy; Charles, Bruce.

In: Therapeutic Drug Monitoring, Vol. 28, No. 6, 12.2006, p. 793-799.

Research output: Contribution to journalArticle

@article{a18ea30801b4487e8597bb990afc65e7,
title = "Application of routine monitoring data for determination of the population pharmacokinetics and enteral bioavailability of phenytoin in neonates and infants with seizures",
abstract = "This study investigated the population pharmacokinetics and the enteral bioavailability of phenytoin (PTN) in neonates and infants with seizures. Data from 83 patients were obtained retrospectively from medical records. A 1-compartment model was fitted to the log-transformed concentration data using NONMEM. Between-subject variability and interoccasion variability were modelled exponentially together with a log transform, both-sides exponential residual unexplained variance model. Covariates in nested models were screened for significance. Model robustness was assessed by bootstrapping with replacement (n = 500) from the study data. The parameters of the final pharmacokinetic model were clearance (L/h) = 0.826·[weight (WT, kg) ÷ 70]·[1 + 0.0692·(postnatal age (d) - 11)]; volume of distribution (L) = 74.2·[WT (kg) ÷ 70]; absolute enteral bioavailability = 0.76; absorption rate constant (h) = 0.167. The between-subject variability for clearance and volume of distribution was 74.2{\%} and 65.6{\%}, respectively. The interoccasion variability for clearance was 54.4{\%}. The unexplained variability was 51.1{\%}. Final model parameter values deviated from median bootstrap estimates by less than 9{\%}. Phenytoin disposition in neonates and infants can be described satisfactorily by linear pharmacokinetics. The values of allometrically scaled clearance and volume were similar to adult values, suggesting no major kinetic differences between adults and infants on the basis of size alone. Postnatal age independently influenced clearance. Switching from enteral to intravenous routes may require a dosage adjustment. The results of this study provide a basis for more rational prescribing of phenytoin in infants and neonates.",
keywords = "Enteral bioavailability, Infants, NONMEM, Pharmacokinetics, Phenytoin",
author = "Za'abi, {Mohammed Al} and Anders Lanner and Xiao Xiaonian and Timothy Donovan and Bruce Charles",
year = "2006",
month = "12",
doi = "10.1097/01.ftd.0000249948.95749.f3",
language = "English",
volume = "28",
pages = "793--799",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Application of routine monitoring data for determination of the population pharmacokinetics and enteral bioavailability of phenytoin in neonates and infants with seizures

AU - Za'abi, Mohammed Al

AU - Lanner, Anders

AU - Xiaonian, Xiao

AU - Donovan, Timothy

AU - Charles, Bruce

PY - 2006/12

Y1 - 2006/12

N2 - This study investigated the population pharmacokinetics and the enteral bioavailability of phenytoin (PTN) in neonates and infants with seizures. Data from 83 patients were obtained retrospectively from medical records. A 1-compartment model was fitted to the log-transformed concentration data using NONMEM. Between-subject variability and interoccasion variability were modelled exponentially together with a log transform, both-sides exponential residual unexplained variance model. Covariates in nested models were screened for significance. Model robustness was assessed by bootstrapping with replacement (n = 500) from the study data. The parameters of the final pharmacokinetic model were clearance (L/h) = 0.826·[weight (WT, kg) ÷ 70]·[1 + 0.0692·(postnatal age (d) - 11)]; volume of distribution (L) = 74.2·[WT (kg) ÷ 70]; absolute enteral bioavailability = 0.76; absorption rate constant (h) = 0.167. The between-subject variability for clearance and volume of distribution was 74.2% and 65.6%, respectively. The interoccasion variability for clearance was 54.4%. The unexplained variability was 51.1%. Final model parameter values deviated from median bootstrap estimates by less than 9%. Phenytoin disposition in neonates and infants can be described satisfactorily by linear pharmacokinetics. The values of allometrically scaled clearance and volume were similar to adult values, suggesting no major kinetic differences between adults and infants on the basis of size alone. Postnatal age independently influenced clearance. Switching from enteral to intravenous routes may require a dosage adjustment. The results of this study provide a basis for more rational prescribing of phenytoin in infants and neonates.

AB - This study investigated the population pharmacokinetics and the enteral bioavailability of phenytoin (PTN) in neonates and infants with seizures. Data from 83 patients were obtained retrospectively from medical records. A 1-compartment model was fitted to the log-transformed concentration data using NONMEM. Between-subject variability and interoccasion variability were modelled exponentially together with a log transform, both-sides exponential residual unexplained variance model. Covariates in nested models were screened for significance. Model robustness was assessed by bootstrapping with replacement (n = 500) from the study data. The parameters of the final pharmacokinetic model were clearance (L/h) = 0.826·[weight (WT, kg) ÷ 70]·[1 + 0.0692·(postnatal age (d) - 11)]; volume of distribution (L) = 74.2·[WT (kg) ÷ 70]; absolute enteral bioavailability = 0.76; absorption rate constant (h) = 0.167. The between-subject variability for clearance and volume of distribution was 74.2% and 65.6%, respectively. The interoccasion variability for clearance was 54.4%. The unexplained variability was 51.1%. Final model parameter values deviated from median bootstrap estimates by less than 9%. Phenytoin disposition in neonates and infants can be described satisfactorily by linear pharmacokinetics. The values of allometrically scaled clearance and volume were similar to adult values, suggesting no major kinetic differences between adults and infants on the basis of size alone. Postnatal age independently influenced clearance. Switching from enteral to intravenous routes may require a dosage adjustment. The results of this study provide a basis for more rational prescribing of phenytoin in infants and neonates.

KW - Enteral bioavailability

KW - Infants

KW - NONMEM

KW - Pharmacokinetics

KW - Phenytoin

UR - http://www.scopus.com/inward/record.url?scp=33845688498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845688498&partnerID=8YFLogxK

U2 - 10.1097/01.ftd.0000249948.95749.f3

DO - 10.1097/01.ftd.0000249948.95749.f3

M3 - Article

C2 - 17164696

AN - SCOPUS:33845688498

VL - 28

SP - 793

EP - 799

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 6

ER -